US 12,059,495 B2
Use of a platelet dry powder for relieving inflammation or injury in a portion of respiratory tract (or the airway)
Chin-Ho Chen, New Taipei (TW); Yi-Shin Tsai, New Taipei (TW); Tzu-Min Yang, New Taipei (TW); and Dao Lung Steven Lin, New Taipei (TW)
Assigned to SPIRIT SCIENTIFIC CO. LTD., New Taipei (TW); and Dao Lung Steven Lin, New Taipei (TW)
Filed by Spirit Scientific Co. LTD., New Taipei (TW); and Dao Lung Steven Lin, New Taipei (TW)
Filed on Jun. 16, 2022, as Appl. No. 17/841,941.
Claims priority of provisional application 63/212,250, filed on Jun. 18, 2021.
Prior Publication US 2022/0401359 A1, Dec. 22, 2022
Int. Cl. A61K 9/00 (2006.01); A61K 35/19 (2015.01); A61K 38/18 (2006.01); A61P 11/00 (2006.01)
CPC A61K 9/0078 (2013.01) [A61K 35/19 (2013.01); A61K 38/1808 (2013.01); A61K 38/1825 (2013.01); A61K 38/1858 (2013.01); A61K 38/1866 (2013.01); A61P 11/00 (2018.01)] 19 Claims
 
1. A method of administering aerosols enriched in growth factors to a respiratory portion of a subject in need thereof, comprising:
(A) mixing a platelet dry powder with a solvent to obtain a platelet dry powder solution/suspension, wherein a number of platelets per gram (g) of the platelet dry powder is 1×106 to 1×1012 (1,000,000 to 1,000,000,000,000), and a number of white blood cells (WBC) per gram (g) of the platelet dry powder is 0-3,000;
(B) nebulizing the platelet dry powder solution/suspension with an aerosol generator to obtain a plurality of aerosols; and
(C) administering the aerosols to the respiratory portion of the subject in an amount that is effective in relieving or treating inflammation or injury of the respiratory portion of the subject.